Index/Organizations/Office of Prescription Drug Promotion

Office of Prescription Drug Promotion

Fact-Checks

6 results
Jan 31, 2026

Which regulatory or legal actions have targeted companies running fake medical‑endorsement ads?

Federal regulators and civil litigants have increasingly targeted companies that use through coordinated enforcement tools: the has issued rulemaking, warning letters, settlements and a and testimonia...

Jan 27, 2026

What legal avenues exist for individuals harmed by false prescription drug ads on social media?

Individuals harmed by on social media have a growing but incomplete set of legal avenues: regulatory complaints to federal agencies such as the and the , potential civil penalties under newly proposed...

Nov 28, 2025

What specific violations did the FDA cite in Neurocept's warning letter?

Available sources in the search set do not include Neurocept’s specific FDA warning letter or a detailed list of violations against Neurocept; therefore this response summarizes what the FDA has been ...

Nov 28, 2025

Did the FDA issue any warning letters to Neurocept after November 2025?

Available reporting and public FDA pages in the provided results do not mention any FDA warning letters addressed to a company named Neurocept after November 2025; the FDA’s central Warning Letters in...

Nov 28, 2025

Has the FDA issued any warning letters to Neurocept in 2024 or 2025, and what were the violations cited?

Available sources do not list any FDA warning letter specifically addressed to a company named “Neurocept” in 2024 or 2025; the FDA warning-letter repositories and industry roundups cited here discuss...

Nov 13, 2025

Has the FDA issued any warning letters or communications mentioning Neurocept in 2023 2024 2025?

The provided analyses consistently report based on the supplied datasets and searches. The conclusion rests on multiple independent checks within the supplied material but is qualified by clear caveat...